AbbVie Hepatitis C Combo Cures Almost All in Late Study
This article is for subscribers only.
AbbVie Inc.’s combination hepatitis C therapy cured almost all patients in a late-stage study, moving the company closer to marketing a treatment that will compete with Gilead Sciences Inc. and Bristol-Myers Squibb Co.
In a trial in 419 patients, AbbVie’s as-yet-unnamed drug cocktail cured 99 percent of those given it after 12 weeks, regardless of whether they added the older booster medicine ribavirin, the North Chicago-based company said yesterday at the Conference on Retroviruses and Opportunistic Infections in Boston. AbbVie said it will seek U.S. approval next quarter.